• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Beta Bionics closes $100M Series D to support bionic pancreas

August 31, 2023 By Sean Whooley

Beta Bionics iLet Dexcom G6 Convatec infusion set
The iLet Bionic Pancreas with a Dexcom G6 CGM and Convatec infusion set. [Image courtesy of Convatec/Beta Bionics]
Beta Bionics announced that it successfully closed a Series D funding round, securing $100 million in new equity capital.

Concord, Massachusetts-based Beta Bionics develops its flagship iLet bionic pancreas. The autonomous insulin delivery system streamlines diabetes management and reduces the burden on patients and physicians. iLet received FDA clearance in May.

While Beta Bionics did not list an intended use of proceeds, the Series D funds could go toward commercialization efforts for iLet.

New investors Sands Capital and Omega Funds co-led the Series D, while new investor Marshall Wace also participated. Other participation came from previous investors Soleus Capital, Eventide Asset Management, Farallon Capital, Perceptive Advisors, certain funds managed by RTW Investments, ArrowMark Partners and Pura Vida Investments.

“This significant investment represents a powerful vote of confidence in Beta Bionics’ mission to redefine diabetes management with user-centric technologies,” Beta Bionics CEO Sean Saint said in a news release. “We are deeply grateful to our investors for recognizing the immense potential of our products. We are eager to push the boundaries of what’s possible by expanding access to the iLet Bionic Pancreas nationwide and further develop and test the bi-hormonal bionic pancreas.”

More about the Beta Bionics iLet

With iLet, users only need to input their weight before the system does the rest. It eliminates the need for healthcare providers to determine complex settings like correction factors, insulin-to-carb ratios or pre-set basal rates. Users can “go bionic” with their diabetes management, requiring no carb counting or insulin correction calculations. iLet determines 100% of the insulin doses throughout the day.

The system uses an adaptive, closed-loop algorithm. It initializes with the user’s body weight and requires no additional insulin dosing parameters. The algorithm removes the need to manually adjust insulin pump therapy settings and variables.

iLet simplifies mealtime use by replacing conventional carb counting with its meal announcement feature. This enables users to estimate the amount of carbs in their meal, categorized as “small,” “medium” or “large.” Over time, the algorithm learns to respond to users’ individual insulin needs.

iLet currently pairs with the Dexcom G6 CGM. It also integrates with an infusion set from Convatec, as announced shortly after FDA clearance. Convatec’s inset, an all-in-one infusion set with a built-in insertion device, connects to iLet on one end and the infusion site at the other. It features a soft, indwelling cannula. Convatec’s contact detach comes with a thin, stainless steel needle. Both infusion sets use kink-free infusion tubing to ensure uninterrupted insulin infusion. They also feature a skin-friendly adhesive tape to secure the set firmly at the infusion site.

Former interim CEO and board member Martha Aronson last year told Drug Delivery Business News that the iLet will help those with diabetes reduce the cognitive burden of managing their disease.

The state of play in the insulin pump space

Competition continues to brew in the insulin pump market. Over the past year or two, we’ve seen a bit of an insulin pump boom. Most recently, a new pump — Mobi from Tandem Diabetes Care — entered the market with FDA clearance last month. On top of Tandem’s offerings, both Insulet and Medtronic are making waves in automated insulin delivery.

Insulet’s Omnipod 5 became the first available tubeless, wearable, automated insulin delivery system after the FDA cleared it in January 2022. In April, the company won FDA clearance for the Omnipod GO long-acting insulin delivery device. The new patch pump covers the basal-only insulin population that takes daily injections of long-acting insulin.

Medtronic, meanwhile, made huge strides with the FDA approval of its MiniMed 780G automated insulin delivery system in April. Not long after, the company looked to expand its automated insulin delivery offerings with the planned $738 million acquisition of EOFlow.

Korea-based EOFlow develops the EOPatch, a tubless, wearable and fully disposable insulin delivery device. While EOPatch holds authorization in a number of geographies, it remains unavailable commercially in the U.S. The company submitted the insulin delivery device for U.S. FDA clearance in January.

When Medtronic announced the planned acquisition, investors reacted negatively to the likes of Insulet and Tandem, suggesting a power shift in automated insulin delivery. However, analysts quelled those reservations at the time, calling it “an overreaction.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Patient Monitoring, Technology Tagged With: Beta Bionics

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS